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Supplementary table 1. Number of participants with missing data for variables. 1 
 Metformin users, n=21 
n (%) 




Age at diagnosis  0 4 (3.3) 4 (2.8) 
Sex 0 0 0 
Method of diagnosis 0 1 (0.8) 1 (0.7) 
WHO performance status 4 (19.0) 30 (25.0) 34 (24.1) 
AJCC staging 5 (23.8) 29 (24.2) 34 (24.1) 
Tumour site in pancreas 0 2 (1.6) 2 (1.4) 





Abdominal lymph node 
























Number of lesions 










Baseline CA19-9  7 (33.3) 39 (32.5) 46 (32.6) 
Baseline eGFR  1 (4.8) 0 1 (0.7) 













Cigarette smoking status 4 (19.0) 33 (27.5) 37 (26.2) 
Outpatient visits 0 6 (5.0) 6 (4.3) 
Hospital admissions  0 8 (6.7) 8 (5.7) 





























































Pancreatic enzyme supplement 
At diagnosis 
In follow-up 
 
0 
0 
 
0 
7 (5.8) 
 
0 
7 (5.0) 
Opiates 
At diagnosis 
In follow-up 
 
0 
0 
 
3 (2.5) 
7 (5.8) 
 
3 (2.1) 
7 (5.0) 
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